Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

MS Brose, B Robinson, SI Sherman… - The Lancet …, 2021 - thelancet.com
Background Patients with radioiodine-refractory differentiated thyroid cancer (DTC)
previously treated with vascular endothelial growth factor receptor (VEGFR)-targeted …
被引用次数：189 相关文章

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.

MS Brose, B Robinson, SI Sherman… - The Lancet …, 2021 - europepmc.org
Background Patients with radioiodine-refractory differentiated thyroid cancer (DTC)
previously treated with vascular endothelial growth factor receptor (VEGFR)-targeted …

[引用][C] Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

MS Brose, B Robinson, SI Sherman, J Krajewska… - The Lancet …, 2021 - cir.nii.ac.jp
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a
randomised, double-blind, placebo-controlled, phase 3 trial | CiNii Research CiNii 国立情報学 …

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

MS Brose, B Robinson, SI Sherman… - The lancet …, 2021 - mdanderson.elsevierpure.com
Background: Patients with radioiodine-refractory differentiated thyroid cancer (DTC)
previously treated with vascular endothelial growth factor receptor (VEGFR)-targeted …

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

MS BROSE, B ROBINSON, J KRAJEWSKA, CC LIN… - 2021 - observatorio.fm.usp.br
Background Patients with radioiodine-refractory differentiated thyroid cancer (DTC)
previously treated with vascular endothelial growth factor receptor (VEGFR)-targeted …

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

MS Brose, B Robinson, SI Sherman… - The Lancet …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Patients with radioiodine-refractory differentiated thyroid cancer (DTC)
previously treated with vascular endothelial growth factor receptor (VEGFR)-targeted …

[引用][C] Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

MS Brose, B Robinson, SI Sherman, J Krajewska… - The Lancet …, 2021 - elibrary.ru
The study was sponsored by Exelixis (Alameda, CA, USA). We thank the patients, their
families, the investigators, and site staff. We thank Suvajit Sen, PhD (Exelixis, Alameda, CA …

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

MS Brose, B Robinson, SI Sherman, J Krajewska… - The Lancet …, 2021 - Elsevier
Background Patients with radioiodine-refractory differentiated thyroid cancer (DTC)
previously treated with vascular endothelial growth factor receptor (VEGFR)-targeted …

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

MS Brose, B Robinson, SI Sherman… - The Lancet …, 2021 - snucm.elsevierpure.com
Background: Patients with radioiodine-refractory differentiated thyroid cancer (DTC)
previously treated with vascular endothelial growth factor receptor (VEGFR)-targeted …

Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

MS BROSE, B ROBINSON, J KRAJEWSKA… - Lancet …, 2021 - observatorio.fm.usp.br
Background Patients with radioiodine-refractory differentiated thyroid cancer (DTC)
previously treated with vascular endothelial growth factor receptor (VEGFR)-targeted …